Direct Comparison in Skin Infection Trials
Sivextro (tedizolid) and Zyvox (linezolid) show comparable clinical efficacy for acute bacterial skin and skin structure infections (ABSSSI). In the ESTABLISH-1 trial, Sivextro achieved 92.6% early clinical response (48-72 hours post-therapy) versus 90% for Zyvox, meeting non-inferiority criteria.[1] ESTABLISH-2 reported 91.5% for Sivextro and 90.8% for Zyvox, also non-inferior.[1][2] No head-to-head superiority data exists; both treat MRSA effectively, with success rates over 90% in phase 3 studies.
How Do Cure Rates Differ Long-Term?
Late clinical response (7-14 days post-therapy) was similar: 87.5% for Sivextro vs 88.6% for Zyvox in ESTABLISH-1, and 85.1% vs 86.5% in ESTABLISH-2.[1] Microbiologic eradication rates for pathogens like MRSA were nearly identical (Sivextro 90-92%, Zyvox 91-93%).[2] Real-world studies, like a 2021 retrospective analysis, found no significant efficacy gap in complicated skin infections.[3]
Why Might Doctors Pick One Over the Other?
Sivextro requires only 6 days of dosing (200 mg daily) versus 10-14 days for Zyvox (600 mg twice daily), potentially improving adherence.[1] Both have similar MRSA MIC90 values (0.5 mcg/mL), but Sivextro shows less in vitro resistance emergence after serial passage.[4] Zyvox has broader historical use and IV/oral options, while Sivextro is IV/oral too but newer (FDA-approved 2014 vs Zyvox 2000).[5]
What About Tolerability and Resistance Risks?
Sivextro causes less nausea (4-7% vs 8-10% for Zyvox) and fewer GI side effects overall.[1][2] Both carry black-box warnings for myelosuppression, but Sivextro's shorter course reduces cumulative risk (e.g., thrombocytopenia in <2% vs 3-8% for longer Zyvox regimens).[6] Resistance patterns favor neither decisively; MRSA resistance to linezolid is ~0.5-1% globally, with tedizolid retaining activity against some linezolid-resistant strains.[4]
When Does Cost or Availability Matter?
Zyvox generics (since 2015) cost $50-200 for a course; Sivextro remains branded at $2,000-3,000 for 6 days, though patient assistance cuts this.[7] No patent expiry issues for Zyvox generics; Sivextro's key patents expire around 2028.[8] Insurance often prefers Zyvox for cost in uncomplicated cases.
[1] ESTABLISH-1/2 Trials, NEJM 2014
[2] FDA Label, Sivextro
[3] Real-World Study, JAC 2021
[4] In Vitro Data, AAC 2012
[5] FDA Approval Histories
[6] Zyvox Label
[7] GoodRx Pricing Data
[8] DrugPatentWatch.com - Sivextro Patents